We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
DL-Phenylalanine
A 50/50 racemic mix of L- and D-phenylalanine marketed for mood and pain. The L-form is a catecholamine (dopamine/noradrenaline) precursor; the D-form is thought to inhibit enkephalinase (slowing endorphin breakdown). The human evidence is genuinely old, small, and mixed — a few decades-old trials, no modern replication.
What the evidence says
Most DLPA studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1979–2015 with a typical study size of 181 participants.
Based on 4 studies · 1 RCT · 221 total participants
Confidence
Low confidenceBy outcome
Scores 3/Emerging because mood claims rest on a single 1979 placebo-free comparison trial, the pain rationale is a hypothesis paper, and the best-evidenced phenylalanine use is dermatologic, not mood or pain.
No trials currently enrolling · 7 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for DLPA, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
DL-phenylalanine (DLPA) is a racemic blend of the essential amino acid L-phenylalanine and its synthetic mirror-image D-phenylalanine. L-phenylalanine is a precursor in the synthesis of tyrosine, dopamine, and noradrenaline, which underpins its marketing for low mood and depression.
D-phenylalanine is proposed to inhibit enkephalinase — the enzyme that degrades endogenous opioids (enkephalins/endorphins) — which is the rationale for its use in chronic pain. The honest reality: the clinical literature is thin and dated.
The most-cited mood study is a 1979 double-blind trial of DL-phenylalanine versus imipramine in 40 depressed patients (no placebo arm, methodological caveats noted by the authors themselves). The pain rationale rests largely on a mechanistic hypothesis paper rather than robust trials.
The best-evidenced use of phenylalanine is actually dermatologic — oral L-phenylalanine combined with UVA light for vitiligo repigmentation — which is a different indication entirely.
There is no modern, adequately-powered, placebo-controlled trial supporting DLPA for mood or pain, so the overall evidence remains emerging.
L-phenylalanine feeds the tyrosine → L-DOPA → dopamine → noradrenaline pathway, the rationale for mood effects.
D-phenylalanine is proposed to slow breakdown of endogenous enkephalins/endorphins, the rationale for pain/analgesia use.
How DLPA works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Absolutely avoid — cannot metabolize phenylalanine.
Avoid or use only under medical supervision.
Not studied at supplemental doses — avoid.
As a catecholamine precursor, phenylalanine combined with MAOIs could raise blood pressure (hypertensive risk). Avoid.
Large neutral amino acids including phenylalanine can compete with levodopa for intestinal and blood-brain-barrier transport, potentially reducing its effect.
Phenylalanine loading has been associated with worsening of tardive dyskinesia in some reports — use caution.
Tip: Take with a small amount of food if needed
Tip: Reduce dose
Tip: Dose earlier in the day; lower dose
DLPA has an evidence score of 3/10 — emerging evidence based on 4 indexed studies. A 50/50 racemic mix of L- and D-phenylalanine marketed for mood and pain. The L-form is a catecholamine (dopamine/noradrenaline) precursor; the D-form is thought to inhibit enkephalinase (slowing endorphin breakdown). The human evidence is genuinely old, small, and mixed — a few decades-old trials, no modern replication. Representative study: PMID 387000.
The commonly studied dose of DLPA is Commonly 500-1500mg daily (no trial-validated dose for mood). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take DLPA is in the morning. It can be taken on an empty stomach. Often taken on an empty stomach so the amino acid is not out-competed by dietary protein for absorption/transport; no validated regimen exists.
DLPA is generally safe at recommended doses, with a few precautions worth noting. Reported side effects are uncommon and include mild GI upset, headache, anxiety/jitteriness or insomnia (overstimulation). Use caution if any of these apply to you: Phenylketonuria (PKU) — absolute contraindication; Pregnancy/breastfeeding (not studied); Concurrent MAOI use.
Phosphatidylserine
Mostly mechanism / observationalKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Soy Isoflavones
Likely helpsPlant compounds with weak estrogenic effects that support menopausal symptoms, bone health, and cardiovascular function.
DHEA
Probably helpsAdrenal hormone precursor that declines with age, supporting hormone balance, energy, and body composition.
Theacrine
Mostly mechanism / observationalCaffeine-like purine alkaloid from kucha tea. Small RCTs suggest subjective energy and mood benefits and good safety, but objective performance gains are inconsistent.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 4 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research